ASH 2023 | Retrospective analysis of clinical outcomes in pts with LBCL receiving CAR-T or autoSCT while in CR
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the findings of a retrospective analysis aimed at investigating the difference in clinical outcomes in patients with relapsed large B-cell lymphoma (LBCL) who received CAR T-cell therapy or an autologous stem cell transplant (autoSCT) while in complete remission (CR). In these patients, autoSCT resulted in improved progression-free survival (PFS) and lower relapse rate. Dr Shadman discusses the implications of these findings, along with the limitations of the analysis, and comments on which patients should receive CAR T-cell therapy and which should undergo autoSCT. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Eli Lilly, BeiGene, Fate Therapeutics, Janssen, Kite, a Gilead Company, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, ADC therapeutics, Genentech, AbbVie, MEI Pharma, Regeneron; Research Funding: BeiGene, Bristol Myers Squibb, MorphoSys/Incyte, AstraZeneca, Pharmacyclics, Mustang Bio, Genmab, Vincerx, Genentech, AbbVie, TG Therapeutics.
